Sort   by:  
 Page size 
UnknownP923: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN LOCOMMOTION AND MOMMENT FOR PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
Not available
S-EPMC10430900 | biostudies-literature
UnknownHealth-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.
Not available
S-EPMC8078427 | biostudies-literature
UnknownPrognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Not available
S-EPMC8832474 | biostudies-literature
UnknownComparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent.
Not available
S-EPMC12858606 | biostudies-literature
UnknownDaratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Not available
S-EPMC10045721 | biostudies-literature
UnknownTriplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
Not available
S-EPMC10040899 | biostudies-literature
Sort   by:  
 Page size